# EDGAR Filing Document

**Accession Number:** 0001053691
**File Stem:** 0000000000-25-010383
**Filing Date:** 2025-9
**Character Count:** 2239
**Document Hash:** 753d6cf4426cd36e591627403b23a6d2
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-010383.hdr.sgml**: 20260211

**ACCESSION NUMBER**: 0000000000-25-010383

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250924

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CervoMed Inc.
- **CENTRAL INDEX KEY:** 0001053691
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 300645032
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 001-37942

**BUSINESS ADDRESS:**
- **STREET 1:** 20 PARK PLAZA
- **STREET 2:** SUITE 424
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02116
- **BUSINESS PHONE:** (617) 744-4400

**MAIL ADDRESS:**
- **STREET 1:** 20 PARK PLAZA
- **STREET 2:** SUITE 424
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02116

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Diffusion Pharmaceuticals Inc.
- **DATE OF NAME CHANGE:** 20160115

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** RestorGenex Corp
- **DATE OF NAME CHANGE:** 20140307

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Stratus Media Group, Inc
- **DATE OF NAME CHANGE:** 20080722
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001437749-25-007829

## Text-Extract

```

                                                        September 24, 2025

William Elder
CFO and General Counsel
CervoMed Inc.
20 Park Plaza
Suite 424
Boston, MA 02116

       Re: CervoMed Inc.
           Form 10-K for the year ended December 31, 2024
           Filed March 17, 2025
           File No. 001-37942
Dear William Elder:

       We have completed our review of your filing. We remind you that the
company and
its management are responsible for the accuracy and adequacy of their
disclosures,
notwithstanding any review, comments, action or absence of action by the staff.

                                                        Sincerely,

                                                        Division of Corporation
Finance
                                                        Office of Life Sciences

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._